Crohn’s Disease Pipeline Insights, FDA Approvals, Drugs, Companies Report | DelveInsight
The leading Crohn's Disease companies such as Janssen, RedHill Biopharma, Amgen, Pfizer, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, Abbvie, Mesoblast, Alfasigma, ...
Pharmabiz1 天
EMA validates X4 Pharma’s marketing authorization application for mavorixafor to treat ...
EMA validates X4 Pharma’s marketing authorization application for mavorixafor to treat WHIM syndrome: Boston Monday, January 27, 2025, 11:00 Hrs [IST] X4 Pharmaceuticals, a comp ...
X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA ...
Submission supported by positive results from global, Phase 3 4WHIM clinical trial;U.S. regulatory approval in WHIM syndrome granted in ...
Healio5 天
‘Readily available biomarker’ can predict outcomes in multiple myeloma
Peripheral blood absolute lymphocyte count at diagnosis is an effective biomarker that can be used to risk-stratify patients with multiple myeloma, according to retrospective study results.Continued ...
Medscape6 天
Myeloma: Can Lymphopenia Help Predict Patient Outcomes?
Standard induction therapy with lenalidomide, bortezomib, and dexamethasone did not overcome inferior outcomes in patients ...